Bio-Path Holdings (BPTH) Provides Key Clinical Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. CMG
8. KLAC
9. BIIB
10. ETSY

Go back to Bio-Path Holdings (BPTH) Provides Key Clinical Updates

Bio-Path Holdings Provides Key Clinical Updates

February 13, 2025 8:00 AM EST

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease

Reports Continued Patient Progress from Phase 2 Triple Combination Study of Prexigebersen in Acute Myeloid Leukemia (AML)

HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) --  Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today provides an update from the Companys... More